Radioimmunoguided Surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: Past, present, and future

Journal of Surgical Oncology

Volumn 96, Issue 4, 2007, Pages 297-308

  Sun, Duxin ^a   Bloomston, Mark ^b   Hinkle, George ^a   Al Saif, Osama Habib ^b   Hall, Nathan C ^b   Povoski, Stephen P ^b   Arnold, Mark W ^b   Martin Jr , Edward W ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

CC49; PET; RIGS; Surgery

Indexed keywords

9H (1,3 DICHLORO 9,9 DIMETHYLACRIDIN 2 ON 7 YL) BETA DEXTRO GALACTOPYRANOSIDE; EDRECOLOMAB; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; HUMANIZED MONOCLONAL ANTIBODY CC49; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AB; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC83; MONOCLONAL ANTIBODY COL 1; MONOCLONAL ANTIBODY TAG 72; UNCLASSIFIED DRUG; B72.3 ANTIBODY; CANCER ANTIBODY; DIAGNOSTIC AGENT; GLYCOPROTEIN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN 72; TUMOR-ASSOCIATED ANTIGEN 72;

CANCER; CANCER DIAGNOSIS; CANCER MODEL; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FLUORESCENCE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; NONHUMAN; PORTABLE EQUIPMENT; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOIMMUNOGUIDED SURGERY; REVIEW; SCINTILLATION CAMERA; SURVIVAL TIME; ARTICLE; CANCER STAGING; COLORECTAL TUMOR; COMPUTER ASSISTED SURGERY; DRUG EFFECT; FORECASTING; IMMUNOLOGY; PATHOLOGY; RADIOGRAPHY; RADIOIMMUNOASSAY; SCINTISCANNING; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; FLUORESCENCE; FLUORODEOXYGLUCOSE F18; FORECASTING; GAMMA CAMERAS; GLYCOPROTEINS; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; SURGERY, COMPUTER-ASSISTED; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34848830462     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20869     Document Type: Review

References (53)

1. Bertsch DJ, Burak WE, Jr., Young DC, et al.: Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Surgery 1995;118:634-638; discussion 638-639.
2. Bertsch DJ, Burak WE, Jr., Young DC, et al.: Radioimmunoguided surgery for colorectal cancer. Ann Surg Oncol 1996;3:310-316.
3. Gardner B: Five-year survival after extended resection of colon cancer. J Surg Oncol 1987;34:258-261.
4. Arnold MW, Young DC, Hitchcock CL, et al.: Radioimmunoguided surgery in primary colorectal carcinoma: An intraoperative prognostic tool and adjuvant to traditional staging. Am J Surg 1995;170:315-318.
5. Colcher D, Milenic D, Roselli M, et al.: Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res 1989;49:1738-1745.
6. Johnson VG, Schlom J, Paterson AJ, et al.: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850-857.
7. Colcher D, Hand PH, Wunderlich D, et al.: Monoclonal antibodies to human mammary carcinoma associated antigens and their potential uses for diagnosis, prognosis, and therapy. Lab Res Methods Biol Med 1983;8:215-258.
8. Colcher D, Hand PH, Nuti M, et al.: Differential binding to human mammary and nonmammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen. Cancer Invest 1983;1:127-138.
9. Colcher D, Zalutsky M, Kaplan W, et al.: Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res 1983;43:736-742.
10. Muraro R, Kuroki M, Wunderlich D, et al.: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988;48:4588-4596.
11. Roberson PL, Yokoyama S, Rogers BE, et al.: Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts. Cancer Biother Radiopharm 2003;18:239-247.
12. Graves SS, Dearstyne E, Lin Y, et al.: Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 2003;9:3712-3721.
13. Domingo RJ, Reilly RM: Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. Nucl Med Commun 2000;21:89-96.
14. Nieroda CA, Milenic DE, Carrasquillo JA, et al.: Improved tumor radioimmunodetection using a single-chain Fv and gamma-interferon: Potential clinical applications for radioimmunoguided surgery and gamma scanning. Cancer Res 1995;55:2858-2865.
15. Greiner JW, Ullmann CD, Nieroda C, et al.: Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon. Cancer Res 1993;53:600-608.
16. Greiner JW, Guadagni F, Roselli M, et al.: Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma. Dis Colon Rectum 1994;37:S100-S105.
17. Pancino G, Osinaga E, Charpin C, et al.: Purification and characterisation of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83 D4. Br J Cancer 1991;63:390-398.
18. Horan Hand P, Colcher D, Salomon D, et al.: Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res 1985;45:833-840.
19. Colcher D, Keenan AM, Larson SM, et al.: Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res 1984;44:5744-5751.
20. Colcher D, Minelli MF, Roselli M, et al.: Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988;48:4597-4603.
21. Martin EW, Jr., Thurston MO: The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection. Cancer Invest 1996;14:560-571.
22. Martin EW, Jr., Mojzisik CM, Hinkle GH, Jr., et al.: Radioimmunoguided surgery using monoclonal antibody. Am J Surg 1988;156:386-392.
23. Kim JA, Triozzi PL, Martin EW, Jr.: Radioimmunoguided surgery for colorectal cancer. Oncology (Williston Park) 1993;7:55-60; discussion 60:63-64.
24. Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C, et al.: Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum 1987;30:761-764.
25. Martin EW, Jr., Thurston MO: Intraoperative radioimmunodetection. Semin Surg Oncol 1998;15:205-208.
26. Sardi A, Agnone CM, Nieroda CA, et al.: Radioimmunoguided surgery in recurrent colorectal cancer: The role of carcinoembryonic antigen, computerized tomography, and physical examination. South Med J 1989;82:1235-1244.
27. Arnold MW, Schneebaum S, Berens A, et al.: Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 1992;112:624-629; discussion 629-630.
28. Arnold MW, Schneebaum S, Berens A, et al.: Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 1992;216:627-632.
29. Xiao J, Horst S, Hinkle G, et al.: Pharmacokinetics and clinical evaluation of (125)I-radiolabeled humanized CC49 monoclonal antibody (HuCC49DeltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005;20:16-26.
30. Fang L, Holford NH, Hinkle G, et al.: Population pharmacokinetics of humanized monoclonal antibody HuCC49{triangleup}CH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 2007;47:227-237.
31. Khazaeli MB: Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients. Hybridoma 1989;8:231-239.
32. Nieroda CA, Mojzisik C, Sardi A, et al.: Radioimmunoguided surgery in primary colon cancer. Cancer Detect Prev 1990;14:651-656.
33. Cote RJ, Houchens DP, Hitchcock CL, et al.: Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49. Cancer 1996;77:613-620.
34. Arnold MW, Hitchcock CL, Young DC, et al.: Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery. Dis Colon Rectum 1996;39:509-513.
35. Arnold MW, Schneebaum S, Martin EW, Jr.: Radioimmunoguided surgery in the treatment and evaluation of rectal cancer patients. Cancer Control 1996;3:42-45.
36. Cohen AM, Martin EW, Jr., Lavery I, et al.: Radioimmunoguided surgery using iodine 1253 in patients with colorectal cancer. Arch Surg 1991;126:349-352.
37. Schneebaum S, Arnold MW, Houchens DP, et al.: The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 1995;75:2809-2817.
38. LaValle GJ, Martinez DA, Sobel D, et al.: Assessment of disseminated pancreatic cancer: A comparison of traditional exploratory laparotomy and radioimmunoguided surgery. Surgery 1997;122:863-873.
39. Arnold MW, Young DM, Hitchcock CL, et al.: Staging of colorectal cancer: Biology vs. morphology. Dis Colon Rectum 1998;41:1482-1487.
40. Martinez DA, Barbera-Guillem E, LaValle GJ, et al.: Radioimmunoguided surgery for gastrointestinal malignancies: An analysis of 14 years of clinical experience. Cancer Control 1997;4:505-516.
41. Warburg O: On the origin of cancer cells. Science 1956;123:309-314.
42. Weber G: Enzymology of cancer cells (second of two parts). N Engl J Med 1977;296:541-551.
43. Weber G: Enzymology of cancer cells (first of two parts). N Engl J Med 1977;296:486-492.
44. Younes M, Brown RW, Stephenson M, et al.: Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-1051.
45. Younes M, Brown RW, Mody DR, et al.: GLUT1 expression in human breast carcinoma: Correlation with known prognostic markers. Anticancer Res 1995;15:2895-2898.
46. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-693.
47. Haberkorn U, Morr I, Oberdorfer F, et al.: Fluorodeoxyglucose uptake in vitro: Aspects of method and effects of treatment with gemcitabine. J Nucl Med 1994;35:1842-1850.
48. Haberkorn U, Ziegler SI, Oberdorfer F, et al.: FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994;21:827-834.
49. Burt BM, Humm JL, Kooby DA, et al.: Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 2001;3:189-195.
50. Waki A, Fujibayashi Y, Magata Y, et al.: Glucose transporter protein-independent tumor cell accumulation of fluorine-18-AFDG, a lipophilic fluorine-18-FDG analog. J Nucl Med 1998;39:245-250.
51. Younes M, Lechago LV, Somoano JR, et al.: Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164-1167.
52. Gallagher BM, Ansari A, Atkins H, et al.: Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: Tissue distribution and imaging studies in animals. J Nucl Med 1977;18:990-996.
53. Kocak E, Al-Saif O, Satter M, et al.: Image guidance during abdominal exploration for recurrent colorectal cancer. Ann Surg Oncol 2007;14:405-410.